IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Pain in young children has been universally under-recognized due to their inability to
describe or localize pain. Improvements in pharmacological interventions are necessary to
optimize patient and family experience and allow for successful and efficient procedure
completion. This is the first study that will compare three intranasal medications
(Intranasal Midazolam, Dexmedetomidine, and Ketamine) to evaluate the length of stay after
medication administration along with patient and provider satisfaction. The objective of this
study is to demonstrate superior intranasal anxiolysis for pediatric laceration repairs with
the shortest emergency department stay and highest patient and provider satisfaction. Based
on previous studies and medication pharmacokinetics, we hypothesize that Intranasal Ketamine
will have the shortest Emergency Department (ED) stay followed by Midazolam and then
Dexmedetomidine with the longest stay; however, Dexmedetomidine will have the highest patient
and provider satisfaction followed by Ketamine and then Midazolam.